ScreenerHero

BLTEBelite Bio Inc American Depositary Shares

NAS · US · Healthcare · Biotechnology · belitebio.com
161.06USD-4.44%Mkt Cap: 6.49B $P/E: —

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tin…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap6.49B $
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-77.61M $
Revenue/Share—
Last Price161.06 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)75.62
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B8.40
EPS (TTM)-2.64
EPS (Forward)2.14
52W Range
60.0072% of range200.00
52W High200.00 USD
52W Low60.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-10.07%
ROA-9.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.99M $
CapEx (TTM)178.00K $
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio33.56
Quick Ratio—
Book Value/Sh19.29 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)214.00 USD
Upside (mean)+32.9%
Target Range185.00 USD – 270.00 USD
$185.00+32.9% to mean$270.00
# Analysts8
Ownership
Shares Out.40.27M
Float18.89M
Insiders44.06%
Institutions24.17%
Short Interest
Short Ratio6.2d
Short % Float5.45%
Short % Out.2.83%
Shares Short1.13M
Short (prev mo.)1.31M
Technical
SMA 50154.15 (+4.5%)
SMA 200155.16 (+3.8%)
Beta-1.23
S&P 52W Chg18.16%
Avg Vol (30d)166.63K
Avg Vol (10d)193.28K
Technical Indicators
RSI (14)50.5
MACD3.6830
MACD Signal4.0610
MACD Hist.-0.3780
BB Upper176.07 USD
BB Middle161.75 USD
BB Lower147.43 USD
BB Width17.70%
ATR (14)7.210 USD
Vol Ratio (20d)0.62x